sales@businessmarketinsights.com     UK: +442081254005
   

South and Central America Neurological Biomarker Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product (Proteomics Biomarker, Genomics Biomarker, Metabolomics Biomarker, Imaging Biomarker, and Others), Application (Alzheimer’s Disease, Parkinson's Disease, Schizophrenia, Huntington's Disease, Spinal Muscular Atrophy, and Others), and End User (Pharmaceutical and Biotechnology Companies, Clinical Diagnostics, and Research Organizations)

Code: TIPRE00020960 | Pages: 116 | Industry: Biotechnology | Date: Apr 2021
Covid

Market Introduction

Neurological biomarkers are molecules present in the cerebral spinal fluid (CSF) or blood that support the diagnosis of brain disorders and monitor disease progression. This helps in the previous detection of disease, less invasive diagnostics, allows faster drug development, and is expected to be the effective treatment.

 

Market Overview and Dynamics

The South and Central America neurological biomarker market is expected to reach US$ 1,185.28 million by 2027 from US$ 502.07 million in 2019; it is estimated to grow with a CAGR of 11.5% from 2020 to 2027. The growth of the market is attributed to some key driving factors such as rising prevalence of neurological diseases and growing focus on neurological biomarker research. On the other hand, concerns associated with use of biomarkers such as the absence of pre-analytical tests are one of the major factors likely to hinder the market growth during the forecast period.

 

Key Market Segments

The South and Central America neurological biomarker market, based on product, is segmented into proteomics biomarker, genomics biomarker, metabolomics biomarker, imaging biomarker, and others. In 2019, the genomics biomarker segment held the largest share of the market. Moreover, the market for the same segment is expected to grow at the fastest rate during the forecast period.

Based on application, the South and Central America neurological biomarker market is segmented into Alzheimer’s disease, Parkinson's disease, schizophrenia, Huntington's disease, spinal muscular atrophy, and others. The Alzheimer’s disease segment held the largest market share in 2019, and the market for the same segment is anticipated to grow at a significant rate during 2020 –2027.

The South and Central America neurological biomarker market, by end user, is segmented into pharmaceutical and biotechnology companies, clinical diagnostics, and research organizations. In 2019, the pharmaceutical and biotechnology companies segment held the largest share of the market. In addition, the market for the same segment is expected to grow at the fastest rate from 2020 to 2027.

 

Major Sources and Companies Listed

A Few of the primary and secondary sources associated with this report on the South and Central America neurological biomarker market are the Alzheimer’s Disease International (ADI), Brazilian Academy of Neurology and Brazilian Institute of Neuroscience and Neurotechnology (BRAINN).

 

Reasons to buy the report

  • Determine prospective investment areas based on a detailed trend analysis of the South and Central America neurological biomarker market over the next years.
  • Gain an in-depth understanding of the underlying factors driving demand for different addictions therapeutics segments in the top spending countries and identify the opportunities offered by each of them.
  • Strengthen your knowledge of the market in terms of demand drivers, industry trends, and the latest technological developments, among others.
  • Identify the major channels driving the South and Central America neurological biomarker market, providing a clear picture of future opportunities that will help Analyze, resulting in revenue expansion.
  • Channelize resources by focusing on the ongoing programs undertaken by the different countries within the South and Central America neurological biomarker market.

 

SOUTH AND CENTRAL AMERICA NEUROLOGICAL BIOMARKER SEGMENTATION

By Product

  • Proteomics Biomarker
  • Genomics Biomarker
  • Metabolomics Biomarker
  • Imaging Biomarker
  • Others

 

By Application

  • Alzheimer’s Disease
  • Parkinson's Disease
  • Schizophrenia
  • Huntington's Disease
  • Spinal Muscular Atrophy
  • Others

 

By End User

  • Pharmaceutical and Biotechnology Companies
  • Clinical Diagnostics
  • Research Organizations

 

By Country

  • Brazil
  • Argentina
  • Rest of South and Central America

 

Company Profiles

  • Thermo Fisher Scientific Inc.
  • Abbott
  • Bio-Rad Laboratories Inc.
  • QIAGEN
  • Immunarray Pvt. Ltd.
  • Quest Diagnostics Incorporated
  • Perkin Elmer, Inc
  • MERCK KGaA  

1.           Introduction

1.1         Scope of the Study

1.2         The Insight Partners Research Report Guidance

1.3         Market Segmentation

1.3.1        South and Central America Neurological Biomarker Market – By Product

1.3.2        South and Central America Neurological Biomarker Market – By Application

1.3.3        South and Central America Neurological Biomarker Market – By End User

1.3.4        South and Central America Neurological Biomarker Market – By Country

2.           Neurological Biomarker Market – Key Takeaways

3.           Research Methodology

3.1         Coverage

3.2         Secondary Research

3.3         Primary Research

4.           Neurological Biomarker Market – Market Landscape

4.1         Overview

4.2         PEST Analysis

4.2.1        South & Central America

4.3         Expert Opinion

5.           Neurological Biomarker Market – Key Market Dynamics

5.1         Key Market Drivers

5.1.1        Rising Prevalence of Neurological Diseases

5.1.2        Growing Focus on Neurological Biomarker Research

5.2         Key Market Restraints

5.2.1        Concerns Associated with Biomarkers

5.3         Key Market Opportunities

5.3.1        Increasing Awareness of Neurological Diseases Coupled with Developing Healthcare Infrastructure

5.4         Future Trends

5.4.1        The Rising Trend of Precision/Personalized Healthcare

5.5         Impact analysis

6.           Neurological Biomarker Market – South and Central America Analysis

6.1         South and Central America Neurological Biomarker Market Revenue Forecast and Analysis

7.           Neurological Biomarker Market Analysis– by Product

7.1         Overview

7.2         Neurological Biomarker Market Share, By Product, 2019 & 2027 (%)

7.3         Proteomics Biomarker

7.3.1        Overview

7.3.2        Proteomics Biomarker Market Revenue and Forecasts to 2027 (US$ Mn)

7.4         Genomics Biomarker

7.4.1        Overview

7.4.2        Genomics Biomarker Market Revenue and Forecasts to 2027 (US$ Mn)

7.5         Metabolomics Biomarker

7.5.1        Overview

7.5.2        Metabolomics Biomarker Market Revenue and Forecasts to 2027 (US$ Mn)

7.6         Imaging Biomarker

7.6.1        Overview

7.6.2        Imaging Biomarker Market Revenue and Forecasts to 2027 (US$ Mn)

7.7         Others

7.7.1        Overview

7.7.2        Others Market Revenue and Forecasts to 2027 (US$ Mn)

8.           Neurological Biomarker Market Analysis– by Application

8.1         Overview

8.2         Neurological Biomarker Market Share, By Application, 2019 & 2027 (%)

8.3         Alzheimer’s Disease

8.3.1        Overview

8.3.2        Alzheimer’s Disease Market Revenue and Forecasts to 2027 (US$ Mn)

8.4         Parkinson’s Disease

8.4.1        Overview

8.4.2        Parkinson’s Disease Market Revenue and Forecasts to 2027 (US$ Mn)

8.5         Schizophrenia

8.5.1        Overview

8.5.2        Schizophrenia Market Revenue and Forecasts to 2027 (US$ Mn)

8.6         Huntington's Disease

8.6.1        Overview

8.6.2        Huntington's Disease Market Revenue and Forecasts to 2027 (US$ Mn)

8.7         Spinal Muscular Atrophy

8.7.1        Overview

8.7.2        Spinal Muscular Atrophy Market Revenue and Forecasts to 2027 (US$ Mn)

8.8         Others

8.8.1        Overview

8.8.2        Others Market Revenue and Forecasts to 2027 (US$ Mn)

9.           Neurological Biomarker Market Analysis– by End User

9.1         Overview

9.2         Neurological Biomarker Market Share, By End User, 2019 & 2027 (%)

9.3         Pharmaceutical and Biotechnology Companies

9.3.1        Overview

9.3.2        Pharmaceutical and Biotechnology Companies Market Revenue and Forecasts to 2027 (US$ Mn)

9.4         Clinical Diagnostics

9.4.1        Overview

9.4.2        Clinical Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)

9.5         Research Organizations

9.5.1        Overview

9.5.2        Research Organizations Market Revenue and Forecasts to 2027 (US$ Mn)

10.        Neurological Biomarker Market Analysis and Forecasts To 2027 – Geographical Analysis

10.1      South and Central America: Neurological Biomarker Market

10.1.1     Overview

10.1.2     South and Central America: Neurological Biomarker Market - Revenue and Forecast to 2027(US$ Million)

10.1.3     South and Central America: Neurological Biomarker Market, by Product, 2018–2027 (USD Million)

10.1.4     South and Central America: Neurological Biomarker Market, by Application, 2018–2027 (USD Million)

10.1.5     South and Central America: Neurological Biomarker Market, by End User, 2018–2027 (USD Million)

10.1.6     South and Central America: Neurological Biomarker Market, by Country, 2019 & 2027 (%)

10.1.7     Brazil: Neurological Biomarker Market – Revenue and Forecast to 2027 (USD Million)

10.1.7.1       Brazil: Neurological Biomarker Market – Revenue and Forecast to 2027 (USD Million)

10.1.7.2       Brazil: Neurological Biomarker Market, by Product, 2018–2027 (USD Million)

10.1.7.3       Brazil: Neurological Biomarker Market, by Application, 2018–2027 (USD Million)

10.1.7.4       Brazil: Neurological Biomarker Market, by End User, 2018–2027 (USD Million)

10.1.8     Argentina: Neurological Biomarker Market – Revenue and Forecast to 2027 (USD Million)

10.1.8.1       Argentina: Neurological Biomarker Market – Revenue and Forecast to 2027 (USD Million)

10.1.8.2       Argentina: Neurological Biomarker Market, by Product, 2018–2027 (USD Million)

10.1.8.3       Argentina: Neurological Biomarker Market, by Application, 2018–2027 (USD Million)

10.1.8.4       Argentina: Neurological Biomarker Market, by End User, 2018–2027 (USD Million)

11.        Impact of COVID-19 Pandemic on South and Central America Neurological Biomarker Market

11.1      South and Central America: Impact Assessment of COVID-19 Pandemic

12.        Company Profiles

12.1      Thermo Fisher Scientific Inc.

12.1.1     Key Facts

12.1.2     Business Description

12.1.3     Products and Services

12.1.4     Financial Overview

12.1.5     SWOT Analysis

12.1.6     Key Developments

12.2      Abbott

12.2.1     Key Facts

12.2.2     Business Description

12.2.3     Products and Services

12.2.4     Financial Overview

12.2.5     SWOT Analysis

12.2.6     Key Developments

12.3      Bio-Rad Laboratories Inc.

12.3.1     Key Facts

12.3.2     Business Description

12.3.3     Products and Services

12.3.4     Financial Overview

12.3.5     SWOT Analysis

12.3.6     Key Developments

12.4      QIAGEN

12.4.1     Key Facts

12.4.2     Business Description

12.4.3     Products and Services

12.4.4     Financial Overview

12.4.5     SWOT Analysis

12.4.6     Key Developments

12.5      Immunarray Pvt. Ltd.

12.5.1     Key Facts

12.5.2     Business Description

12.5.3     Products and Services

12.5.4     Financial Overview

12.5.5     SWOT Analysis

12.5.6     Key Developments

12.6      Quest Diagnostics Incorporated

12.6.1     Key Facts

12.6.2     Business Description

12.6.3     Products and Services

12.6.4     Financial Overview

12.6.5     SWOT Analysis

12.6.6     Key Developments

12.7      Perkin Elmer, Inc.

12.7.1     Key Facts

12.7.2     Business Description

12.7.3     Products and Services

12.7.4     Financial Overview

12.7.5     SWOT Analysis

12.7.6     Key Developments

12.8      MERCK KGaA

12.8.1     Key Facts

12.8.2     Business Description

12.8.3     Products and Services

12.8.4     Financial Overview

12.8.5     SWOT Analysis

12.8.6     Key Developments

13.        Appendix

13.1      Glossary of Terms

LIST OF TABLES

Table 1.             South and Central America Neurological Biomarker Market, by Product – Revenue and Forecast to 2027(USD Million)

Table 2.             South and Central America Neurological Biomarker Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 3.             South and Central America Neurological Biomarker Market, by End User– Revenue and Forecast to 2027  (USD Million)

Table 4.             Brazil Neurological Biomarker Market, by Product – Revenue and Forecast to 2027 (USD Million)

Table 5.             Brazil Neurological Biomarker Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 6.             Brazil Neurological Biomarker Market, by End User– Revenue and Forecast to 2027 (USD Million)

Table 7.             Argentina Neurological Biomarker Market, by Product – Revenue and Forecast to 2027 (USD Million)

Table 8.             Argentina Neurological Biomarker Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 9.             Argentina Neurological Biomarker Market, by End User– Revenue and Forecast to 2027 (USD Million)

Table 10.          Glossary of Terms, Neurological Biomarker Market

LIST OF FIGURES

Figure 1.           Neurological Biomarker Market Segmentation

Figure 2.           Neurological Biomarker Market – By Country

Figure 3.           South and Central America Neurological Biomarker Market Overview

Figure 4.           Genomic Biomarkers Segment Held Largest Share of Neurological Biomarker Market

Figure 5.           South and Central America Neurological Biomarker Market- Leading Country Markets (US$ Million)

Figure 6.           South & Central America PEST Analysis

Figure 7.           Expert Opinion

Figure 8.           Neurological Biomarker Market Impact Analysis of Driver and Restraint

Figure 9.           South and Central America Neurological Biomarker Market – Revenue Forecast and Analysis – 2019- 2027

Figure 10.        Neurological Biomarker Market Share, by Product, 2019 & 2027 (%)

Figure 11.        Proteomics Biomarker Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 12.        Genomics Biomarker Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 13.        Metabolomics Biomarker Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 14.        Imaging Biomarker Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 15.        Others Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 16.        Neurological Biomarker Market Share, by Application, 2019 & 2027 (%)

Figure 17.        Alzheimer’s Disease Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 18.        Parkinson’s Disease Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 19.        Schizophrenia Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 20.        Huntington's Disease Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 21.        Spinal Muscular Atrophy Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 22.        Others Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 23.        Neurological Biomarker Market Share, by End User, 2019 & 2027 (%)

Figure 24.        Pharmaceutical and Biotechnology Companies Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 25.        Clinical Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 26.        Research Organizations Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 27.        South and Central America: Neurological Biomarker Market, by Key Country – Revenue (2019) (USD Million)

Figure 28.        South and Central America Neurological Biomarker Market Revenue and Forecast to 2027 (USD Million)

Figure 29.        South and Central America: Neurological Biomarker Market, by Country, 2019 & 2027 (%)

Figure 30.        Brazil: Neurological Biomarker Market – Revenue and Forecast to 2027 (USD Million)

Figure 31.        Argentina: Neurological Biomarker Market – Revenue and Forecast to 2027 (USD Million)

Figure 32.           Impact of COVID-19 Pandemic in South and Central America Market

 

  1. Thermo Fisher Scientific Inc.
  2. Abbott
  3. Bio-Rad Laboratories Inc.
  4. QIAGEN
  5. Immunarray Pvt. Ltd.
  6. Quest Diagnostics Incorporated
  7. Perkin Elmer, Inc
  8. MERCK KGaA
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the South and Central America neurological biomarkers market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the South and Central America neurological biomarkers market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

 


Related Tags South and Central America Neurological Biomarker Market South and Central America Neurological Biomarker Market Research South and Central America Neurological Biomarker Market Insight South and Central America Neurological Biomarker Market Trends South and Central America Neurological Biomarker Market Forecast South and Central America Neurological Biomarker Market Share South and Central America Neurological Biomarker Market 2027 South and Central America Neurological Biomarker Market Growth South and Central America Neurological Biomarker Industry Sector South and Central America Neurological Biomarker PDF Report South and Central America Neurological Biomarker Analysis South and Central America Neurological Biomarker Research Competitive Analysis

Purchase Options
Single User License
$3000
Site License
$4000
Enterprise License
$5000